Abcellera Biologics Inc Total Liabilities
Abcellera Biologics Inc total liabilities. Based on the latest financial reports, Abcellera Biologics Inc (ABCL) has total liabilities worth $411.56 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Abcellera Biologics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Abcellera Biologics Inc (2018–2025)
Total liabilities of Abcellera Biologics Inc from 2018 to 2025. This chart illustrates how Abcellera Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Abcellera Biologics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Abcellera Biologics Inc Competitors by Total Liabilities
The table below lists competitors of Abcellera Biologics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kinetik Holdings Inc
NYSE:KNTK
|
USA | $4.27 Billion |
|
Enaex S.A
SN:ENAEX
|
Chile | CL$1.18 Billion |
|
Westgold Resources Ltd
AU:WGX
|
Australia | AU$1.38 Billion |
|
First Capital Real Estate Investment Trust
TO:FCR-UN
|
Canada | CA$4.35 Billion |
|
Taichung Commercial Bank Co Ltd
TW:2812
|
Taiwan | NT$906.42 Billion |
|
GEK TERNA Holdings Real Estate Construction S.A
AT:GEKTERNA
|
Greece | €6.42 Billion |
|
Treasury Wine Estates Ltd
AU:TWE
|
Australia | AU$3.00 Billion |
|
HARBOUR ENE.SP.ADR LS-50
F:PQQ2
|
Germany | €25.54 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Abcellera Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Abcellera Biologics Inc total assets.
Liquidity & Leverage Metrics
Abcellera Biologics Inc Total Liabilities Ratios Explained
Abcellera Biologics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abcellera Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abcellera Biologics Inc (2018–2025)
The table below shows the annual total liabilities of Abcellera Biologics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $390.05 Million | +28.11% |
| 2024-12-31 | $304.47 Million | -9.32% |
| 2023-12-31 | $335.78 Million | +9.15% |
| 2022-12-31 | $307.63 Million | +5.05% |
| 2021-12-31 | $292.84 Million | +67.31% |
| 2020-12-31 | $175.03 Million | +1222.36% |
| 2019-12-31 | $13.24 Million | +33.93% |
| 2018-12-31 | $9.88 Million | -- |
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more